Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.51 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.47 |
| ▸ | TDO2 | P48775 | 4/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1387159 | 0.83 | MAPK14 (0.55) | MAPK14TDO2PTGS1PTGS2PIM1 | |
| SCHEMBL2615985 | 0.81 | CNR2 (0.50) | GRM2TDO2PIM1NOTUMCNR2 | |
| SCHEMBL9953638 | 0.76 | NOTUM (0.47) | MAPK14HCRTR1HCRTR2PTGS1PTGS2 | |
| SCHEMBL1387318 | 0.76 | MAPK14 (0.66) | MAPK14 | |
| SCHEMBL5257164 | 0.72 | GRM2 (0.43) | MAPK14GRM2TDO2PTGS1PTGS2 | |
| SCHEMBL7857724 | 0.72 | LRRK2 (0.58) | MAPK14GRM2MAPK1 | |
| SCHEMBL5255541 | 0.72 | GRM2 (0.46) | MAPK14GRM2TDO2MAPK1 | |
| SCHEMBL11754023 | 0.72 | MAPK14 (0.50) | MAPK14HCRTR1HCRTR2PTGS1PTGS2 | |
| SCHEMBL11754854 | 0.72 | MAPK14 (0.53) | MAPK14HCRTR1HCRTR2PTGS1PTGS2 | |
| SCHEMBL6185308 | 0.69 | MAPK14 (0.70) | MAPK14HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106793-A1 | Oxazoles for treating cytokine mediated diseases | SMITHKLINE BEECHAM CORPORATION | 2004-06-03 | — | — | US | disclosed |
| EP-1306377-A2 | Pyridyl-oxazoles and their use as cytokines inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2003-05-02 | — | — | EP | disclosed |
| US-20020169173-A1 | Oxazoles for treating cytokine mediated diseases | SMITHKLINE BEECHAM CORPORATION | 2002-11-14 | — | — | US | disclosed |
| US-6288062-B1 | INTERLEUKIN AND TUMOR NECROSIS FACTOR INHIBITORS; ANTIINFLAMMATORY AGENTS; RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; RESPIRATORY SYSTEM DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2001-09-11 | — | — | US | disclosed |
| EP-0727998-A4 | OXAZOLES FOR TREATING CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORP (US) | 1997-03-19 | — | — | EP | disclosed |
| EP-0727998-A1 | OXAZOLES FOR TREATING CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1996-08-28 | — | — | EP | disclosed |
| WO-1995013067-A1 | OXAZOLES FOR TREATING CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1995-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106793-A1 | Oxazoles for treating cytokine mediated diseases | IL2, IL17A, IL5 | MAPK14 709/4885GRM2 1780/4885TDO2 746/4885 |
| US-20020169173-A1 | Oxazoles for treating cytokine mediated diseases | IL17A, IL4I1, IL2 | MAPK14 870/4885GRM2 1272/4885TDO2 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.